Amylyx Pharmaceuticals, Inc. (AMLX)
NASDAQ: AMLX · Real-Time Price · USD
31.50
+0.59 (1.91%)
Nov 11, 2026, 1:27 PM EST - Market open
Amylyx Pharmaceuticals Stock Forecast
Stock Price Forecast
According to 12 analysts polled by S&P Global, Amylyx Pharmaceuticals stock has a consensus rating of "Strong Buy" and an average price target of $43. The average 1-year stock price forecast is 36.51% higher than the current stock price, while the lowest is $25 (-20.63%) and the highest is $57 (+80.95%).
Price Target: $43 (+36.51%)
Analyst Consensus: Strong Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Amylyx Pharmaceuticals stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jun '26 | Jul '26 | Aug '26 | Sep '26 | Oct '26 | Nov '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 11 | 10 | 11 | 11 | 11 | 11 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 12 | 11 | 12 | 12 | 12 | 12 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Mizuho Securities | Mizuho Securities | Buy Maintains $38 → $39 | Buy | Maintains | $38 → $39 | +23.81% | Nov 10, 2026 |
| Citi | Citi | Buy Maintains $39 | Buy | Maintains | $39 | +23.81% | Nov 6, 2026 |
| H.C. Wainwright | H.C. Wainwright | Buy Maintains $55 | Buy | Maintains | $55 | +74.60% | Nov 6, 2026 |
| Stifel Nicolaus | Stifel Nicolaus | Buy Maintains $45 | Buy | Maintains | $45 | +42.86% | Oct 1, 2026 |
| Guggenheim | Guggenheim | Buy Reiterates $55 → $57 | Buy | Reiterates | $55 → $57 | +80.95% | Aug 27, 2026 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
28.29M
EPS This Year
-1.50
from -1.53
EPS Next Year
-1.09
from -1.50
EPS and Forward PE are based on non-GAAP adjusted numbers.